Basmisanil CAS：1159600-41-5

Basmisanil(RG1662,RO5186582)is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.As of August 2015,it is in phase II clinical trials for this indication.Down syndrome(DS)is the most commonly identifiable genetic form of intellectual disability.Individuals with DS have considerable deficits in intellectual functioning(i.e.,low intellectual quotient,delayed learning and/or impaired language development)and adaptive behavior.

msds---Basmisanil